BioCentury
ARTICLE | Clinical News

BVT: Phase IIb

May 26, 2003 7:00 AM UTC

Biovitrum and GSK said they would shorten a Sweden Phase IIb trial in 350 patients and then terminate development of the compound for obesity. Biovitrum said it will run the trial for 4 weeks instead ...